Adenomyosis is associated with infertility, but it does not cause infertility in every woman who has it. The relationship is probabilistic, not deterministic. Population studies link adenomyosis to lower pregnancy and live-birth rates, especially in women undergoing assisted reproduction, yet many women with adenomyosis conceive without treatment. The mechanism is partly anatomical and partly inflammatory, and the size of the effect depends heavily on how deep the disease invades the uterine muscle and how many prior pregnancies a woman has had.
The mechanism: why misplaced endometrium disrupts conception
Adenomyosis occurs when endometrial tissue grows inside the myometrium, the muscular wall of the uterus. This ectopic tissue responds to estrogen and progesterone the same way normal endometrium does, bleeding cyclically inside a space with no outlet. The result is a chronically inflamed, enlarging, and mechanically altered uterus.
Three pathways plausibly reduce fertility. First, the inflamed myometrium secretes cytokines and prostaglandins that change the uterine environment, impairing sperm motility and embryo implantation. Second, adenomyotic tissue disrupts the junctional zone, the inner myometrial layer whose coordinated contractions help move sperm and support early implantation. Third, the disease distorts uterine architecture and can reduce endometrial receptivity. These are mechanistic inferences from imaging and histology; direct causal proof in humans is limited by the inability to randomize who develops adenomyosis.
The critical distinction is between the presence of disease and the burden of disease. Focal adenomyosis confined to a small myometrial region may have little reproductive impact. Diffuse disease involving a large share of the myometrium, or disease penetrating near the endometrium, is more consistently associated with impaired implantation. Severity, not merely diagnosis, drives prognosis.
Quantified context: how large is the association
Adenomyosis is common. Imaging and histologic series report prevalence of roughly 20 to 35 percent in women with symptoms, and it is frequently found incidentally in women who conceive naturally. In infertility populations, prevalence estimates vary widely, from about 5 percent to more than 30 percent depending on diagnostic criteria and whether MRI or ultrasound is used.
Outcome studies in assisted reproduction show directionally consistent but variable effects. Meta-analyses of women undergoing in vitro fertilization report lower implantation and clinical pregnancy rates and higher miscarriage rates among those with adenomyosis compared with those without, with live-birth reductions reported in the range of roughly 10 to 30 percent relative, not absolute. These are pooled estimates across heterogeneous studies, so the true effect for any individual is uncertain. The honest summary is that adenomyosis shifts the odds downward modestly in aggregate, with wide individual variation.
Adenomyosis also becomes more common with age and prior uterine instrumentation, which means affected women are often older and more likely to have other fertility factors. Separating the adenomyosis effect from age and coexisting conditions such as endometriosis is difficult and inflates some reported associations.
Comparing adenomyosis with related conditions
| Feature | Adenomyosis | Endometriosis | Fibroids | Normal uterus |
|---|---|---|---|---|
| Tissue location | Endometrium within myometrium | Endometrium outside uterus | Benign myometrial tumor | — |
| Typical fertility effect | Modest reduction in aggregate | Consistent reduction | Variable, depends on size and location | Baseline |
| Diagnostic method | MRI or transvaginal ultrasound | Laparoscopy or imaging | Ultrasound | — |
| Reversibility with treatment | Partial, uncertain | Partial | Usually improves after removal | — |
| Age association | Increases with age and parity | Often younger onset | Increases with age | — |
This comparison matters because adenomyosis is often found alongside endometriosis and fibroids. A diagnosis of adenomyosis alone does not fully explain infertility, and clinicians should evaluate for coexisting conditions before attributing poor outcomes to it.
Edge cases and the counterintuitive finding
The most counterintuitive detail in the literature is that a substantial proportion of women with imaging-confirmed adenomyosis conceive spontaneously. In cohort studies that follow women with adenomyosis who are not seeking treatment, natural conception is common enough that adenomyosis cannot be framed as a stand-alone cause of infertility. This likely reflects that many cases are mild or focal, and that fertility is governed by ovarian reserve, tubal function, and partner factors as much as by uterine disease.
Edge cases sharpen the picture. Severe diffuse adenomyosis with a markedly thickened junctional zone, or disease that has caused significant uterine enlargement, carries a stronger reproductive penalty. Adenomyosis diagnosed in women with recurrent pregnancy loss is a distinct scenario, where the mechanism may be impaired implantation rather than failure to conceive. Women with adenomyosis who also have endometriosis fall into a higher-risk group whose outcomes reflect both conditions.
Common misconceptions
One persistent misconception is that adenomyosis always requires surgery or assisted reproduction before pregnancy is possible. Many women with the condition conceive without intervention, and the diagnosis alone does not mandate treatment.
Another is that the condition is rare or confined to older women. It is frequently found in women of reproductive age, and improved imaging has raised detection rather than true incidence.
A third is that treatment of adenomyosis reliably restores fertility. Treatments such as hormonal suppression, conservative surgery, or uterine artery embolization can reduce symptoms and, in some cases, improve the uterine environment, but none guarantees improved pregnancy rates. The evidence for fertility benefit from most interventions is limited and largely observational.
A fourth is that a normal ultrasound rules out adenomyosis. Early or focal disease can be missed, and MRI detects some cases that ultrasound does not. This does not mean every woman with infertility needs MRI; it means a normal scan is not absolute proof of absence.
Practical actions and red flags
If you have adenomyosis and are trying to conceive, the useful steps are to establish the diagnosis precisely, quantify severity, and screen for coexisting conditions. Request imaging that documents the extent and location of disease, not merely its presence. Ask whether the junctional zone is thickened or whether disease is diffuse versus focal, because severity changes the prognosis.
Screen for other fertility factors before attributing outcomes to adenomyosis: ovarian reserve testing, tubal patency assessment, and partner semen analysis. Adenomyosis rarely acts alone. If you are undergoing assisted reproduction, ask whether your clinic adjusts protocols for adenomyosis, and ask what the evidence base is for that adjustment.
Consider referral to a reproductive endocrinologist when adenomyosis is severe, when there is coexisting endometriosis, or when prior embryo transfers have failed.
Red flags that warrant prompt evaluation:
Rapidly enlarging uterus or new severe pelvic pain Heavy menstrual bleeding causing anemia Repeated early pregnancy loss Fever or signs of infection after any uterine procedure New symptoms suggesting a coexisting condition such as endometriosis or fibroids
Timeline of what to expect
| Stage | Typical timing | What happens |
|---|---|---|
| Symptoms or incidental finding | Variable, often age 30s-40s | Pain, heavy bleeding, or imaging detection |
| Diagnosis | Weeks to months after presentation | Ultrasound or MRI; severity documented |
| Fertility evaluation | Concurrent | Ovarian reserve, tubal, and partner assessment |
| Trial of natural conception | 6-12 months depending on age | Spontaneous pregnancy possible in mild disease |
| Assisted reproduction decision | Months after evaluation | IVF considered if other factors or severe disease |
| Treatment for symptoms | Variable | Hormonal or surgical options, fertility goals guide choice |
The practical takeaway is that adenomyosis should be treated as a risk modifier, not a verdict. Women with mild or focal disease frequently conceive, and women with severe diffuse disease face higher hurdles that warrant earlier specialist involvement.
Limitations of the evidence
The central limitation is that almost all evidence linking adenomyosis to infertility is observational. Randomization is not feasible, so causality is inferred rather than proven. Diagnostic criteria have changed over time, which means older prevalence and outcome figures are not directly comparable to current ones. Many studies are small, single-center, and retrospective.
Another limitation is that adenomyosis is often diagnosed in women already undergoing fertility treatment, which selects for more severe cases and inflates apparent associations. Conversely, incidental detection in women who conceive naturally is underreported. The net effect is that the true population effect size is uncertain, and the pooled estimates should be read as directional rather than precise.
A final caveat is that treatment evidence is thin. Hormonal suppression, conservative surgery, and embolization have symptom benefits, but their effect on live birth is not established by high-quality trials. Clinicians and patients should treat fertility claims for these interventions with appropriate caution. The most defensible position is that adenomyosis modestly reduces the probability of conception and live birth in aggregate, that mild disease often permits natural conception, and that severity and coexisting conditions determine the individual prognosis far more than the diagnosis itself.